AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-02-22 pm EST 5-day change 1st Jan Change
176.8 USD +0.92% Intraday chart for AbbVie Inc. +1.34% +14.05%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Sector Update: Health Care Stocks Gain Late Afternoon MT
AbbVie Plans $13 Billion Bond Sale to Fund Acquisitions MT
AbbVie Ties Up With Tentarix to Develop New Drugs for Oncology, Immunology MT
Morphic Holding's Full Year 2023 Net Loss Widens, Collaboration Revenue Falls MT
Phew! The party continues! Our Logo
Abbvie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology CI
AbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reports RE
AbbVie CEO to Retire; COO Robert Michael Named Successor MT
Disc Medicine Says FDA Grants Fast Track Designation for Investigational Treatment of Chronic Kidney Disease, Anemia MT
Organon's Hadlima Chosen by VA as Substitute for Humira MT
AbbVie Names Robert Michael CEO, Richard Gonzalez Executive Chair MT
AbbVie: new CEO on July 1 CF
AbbVie Names Robert Michael to Succeed Richard Gonzalez as CEO DJ
AbbVie Names President Robert Michael as CEO MT
Abbvie, Inc. Appoints Robert A. Michael as Member of the Board of Directors and Richard A. Gonzalez as Executive Chairman of the Board of Directors CI
AbbVie Inc. Announces Chief Executive Officer Changes CI
Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB... Our Logo
Powell Industries, Inc. : New era for the custom equipment designer? Our Logo
Health Care Stocks Pile On Gains -- Health Care Roundup DJ
AbbVie Maintains Quarterly Dividend at $1.55 Per Share, Payable May 15 to Stockholders of Record on April 15 MT
AbbVie Inc. Declares Quarterly Cash Dividend, Payable on May 15, 2024 CI
Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating MT
BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase AN
Biopharma Credit Secures $51 Million Loan Repayment from US Biotech ImmunoGen MT
Top Stories at Midday: Bezos Sells Nearly 12 Million Amazon Shares; Diamondback's $26 Billion Endeavor Energy Deal; Citigroup's Risk Management Procedures Rebuked; AbbVie Buys ImmunoGen MT
Chart AbbVie Inc.
More charts
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (78.7%), Germany (2.3%), Canada (2%), Japan (1.6%), China (1.6%), France (1.4%), Australia (0.9%), Spain (0.9%), the United Kingdom (0.8%), Italy (0.8%), Brazil (0.7%) and other (8.3%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
176.8 USD
Average target price
178.6 USD
Spread / Average Target
+1.04%
Consensus
1st Jan change Capi.
+14.05% 309 B $
+32.03% 671 B $
+22.22% 538 B $
+2.37% 382 B $
+18.57% 325 B $
-6.40% 211 B $
+6.72% 209 B $
-5.32% 198 B $
-4.31% 156 B $
-0.99% 152 B $
Other Pharmaceuticals
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer